Eugia Pharma Specialities, a wholly-owned subsidiary of Aurobindo Pharma (NSE:AUROPHARMA, BOM:524804), has received final approval from the US Food and Drug Administration (US FDA) to manufacture and market Dasatinib Tablets, according to a Wednesday filing to the Indian stock exchanges.
The drug is bioequivalent and therapeutically equivalent to Bristol-Myers Squibb Company's reference listed drug Sprycel Tablets, which is indicated for treating chronic myelogenous leukemia and acute lymphoblastic leukemia.
The product is expected to be launched in the fiscal first quarter of financial year 2025-26.
The company's shares were up over 3% in recent trade.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。